Congenital Hemangioma. Hemangioma of skin and subcutaneous tissue
Conditions
Interventions
Intervention 1: Intervention group: in this group rapamycin gel , as 1mg of sirolimus ( Pfizer) in gel of 0.2% will be given for using each 12 hrs for 3 month as topical . Intervention 2: Control grou
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Months to 1 Years
Inclusion criteria
Inclusion criteria: Infantile Hemangioma in 1-12 month infants Non complicated hemangiomas Hemangiomas not in need of systemic or surgical treatments Hemangiomas <= 3 cm
Exclusion criteria
Exclusion criteria: Complicated Hemangioma Beta blocker adverse effects Taking other medications interacting beta blockers Cardiac,renal anomalies or asthma History of hypoglycemia Taking oral beta blocker for any reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lesion size. Timepoint: Aforementioned scores will be assessed at the beginning of treatment ( 0) and then each month for 3 month ( 1,2,3) during our treatment period. finally 1 and 3 month later after finished treatment as follow up ( 4,7). Method of measurement: Measured by ruler.;Clinical Score. Timepoint: Aforementioned scores will be assessed at the beginning of treatment ( 0) and then each month for 3 month ( 1,2,3) during our treatment period. finally 1 and 3 month later after finished treatment as follow up ( 4,7). Method of measurement: By this method we assess the pre-treatment and post-treatment size of hemangioma by getting photos of lesions ( by consent) , and then the score will be calculated as below: ( difference between pre and post hemangioma size*100/ pre size). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParisa Hajheidari
Esfahan University of Medical Sciences
Outcome results
None listed